Leadership: Ambitious Minds on an Audacious Mission

Ms. Jones brings more than 25 years of business leadership experience in the biotechnology and pharmaceutical industries across strategic and operational roles. Prior to transitioning to Chief Executive Officer of Neximmune, she held various positions on the executive team, serving as both Chief Operating Officer and Chief Business Officer. For five years prior to joining NexImmune, Ms. Jones was with Astra Zeneca and its subsidiary MedImmune. From 2013-2015, Ms. Jones was Vice President of Portfolio Strategy and Management at AstraZeneca, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the company. Prior to that she served as Vice President of Global Strategic Marketing to shape product plans and prepare MedImmune for multiple launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech, where she worked for 16 years, including Head of Immunology and Ophthalmology in Global Portfolio and Product Strategy, Endocrine and Pulmonary Franchise, and Immunology Business Unit Operations and Pipeline Planning. Ms. Jones also serves in a consulting role for various companies and organizations and serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women.

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. He is also an expert in cellular immunology and T cell research. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing interest developing methods for antigen-specific stimulation of T cells for therapeutic use. He has numerous peer-reviewed publications and is a co-inventor on more than 20 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Prior to joining NexImmune in 2014, Dr. Oelke was, from 2003-2014, on the faculty at the Johns Hopkins University. Earlier in his career Dr. Oelke, who is a chemist by training, received his Ph.D. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in immunotherapy.

Dr. Bednarik has over 30 years of experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer. Prior to that, Dr. Bednarik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednarik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at the Johns Hopkins University Oncology Center.

Dr. Ragheb is the Senior Vice President for Translational Sciences and Medicine at NexImmune and the Scientific Founder of JoMoCo Inc. He previously held the role of Senior Medical Fellow for Immunology at Eli Lilly & Co. Before being recruited to Eli Lilly, he was most recently a Chief Medical Research Officer in the Laboratory of Immunology of the Office of Biotechnology Products, CDER, at the U.S. Food Drug Administration and an Attending Physician on the Allergy-Immunology Service, NIAID. A Senior Clinical Investigator in the Laboratory of Immunology, NEI, at the National Institutes of Health, he is a graduate of the Johns Hopkins University and School of Medicine, and is a diplomate of the American Board of Allergy and Immunology. His work and publications have spanned the fields of retrovirology, gene therapy, immune activation, therapeutic protein immunogenicity and clinical trials in immune tolerance.

Ms. Catterton joins NexImmune with over 20 years of experience in the biotechnology and pharmaceutical industry. During her career, she held positions in executive leadership, risk management, quality management systems, global compliance, design controls and regulatory affairs. Ms. Catterton has worked as an independent consultant for over 15 years to Fortune 500 companies, developing and implementing compliant solutions, dealing with FDA & third-party inspections, Consent Decree and Warning Letter responses and implementation.

Mr. Stover brings over 15 years of accounting, finance, and audit experience serving various life science companies in the U.S. and internationally. Before joining NexImmune, he served as Executive Director, Corporate Controller at Autolus Therapeutics Plc. in London. Mr. Stover served as Director, Financial Reporting for Sucampo Pharmaceuticals, Inc and as Associate Director of External Reporting & Technical Accounting at Iridium Communications Inc. He honed his accounting experience serving as a Senior Manager of Ernst & Young LLP advising U.S. and international companies. Mr. Stover earned a B.A. in Economics from Wittenberg University, a MPA from American University, and is a licensed CPA.

In vitae posuere sapien. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Morbi consectetur lectus at lacus pretium ultrices. Nam ac sem in sapien tempor eleifend. Pellentesque imperdiet felis at cursus fermentum. Vivamus congue, nibh hendrerit efficitur laoreet, libero mauris cursus est, porta blandit urna lectus eget arcu. Nunc non est tortor. Nunc non imperdiet diam. Suspendisse vitae est quis mauris condimentum vulputate et lacinia ex. Sed ullamcorper nisl sed diam rutrum, vel ullamcorper orci imperdiet. Mauris dapibus mi a hendrerit rhoncus. Integer pulvinar massa sit amet eros maximus, id faucibus augue ultricies. Proin vehicula ac nisi non tristique. Cras egestas a odio vitae convallis. Nam commodo justo placerat sapien iaculis, ut blandit metus gravida. Mauris dictum vitae ex quis vehicula.

Ms. Haslbeck brings over 20 years of Human Resource experience and leadership, with over 15 years in the biotechnology and pharmaceutical industries.

Her experience spans startup organizations, pre & post IPO, mergers & acquisitions, as well as established organizations with global presence.
Her expertise has spanned all functions of HR, but she has been instrumental in building commercial, corporate and scientific teams at all levels, as well as Organizational Development initiatives to build and retain both culture and people.

Karen is a Senior Certified Professional in Human Resources (SPHR), is a member of the Society for Human Resource Management (SHRM) and Chesapeake Human Resources Association (CHRA). She also earned a certificate in Employee Relations from Cornell University. Ms. Haslbeck has a Degree in Business Administration from UMBC.

Mr. Schiller has over 20 years of experience in business development, global licensing and commercial development. Most recently, Mr. Schiller served as Director, Global Licensing & Business Development, Immunology at EMD Serono, a business of Merck KGaA. Prior to his time at EMD Serono, Mr. Schiller served as Head of Licensing at Cell Signaling Technology, VP of Business Development at Ensemble Discovery and Senior Director of Business Development at Critical Therapeutics. Mr. Schiller holds a BS in Chemistry from the University of South Florida.